1 week Candel Skyrockets 68% On A Potential First-In-20-Years Cancer Drug Investor's Business Daily
Shares of Candel Therapeutics skyrocketed Wednesday after the biotech company’s prostate cancer treatment succeeded in a Phase 3 study.
The post Candel Skyrockets 68% On A Potential First-In-20-Years Cancer Drug appeared first on Investor's Busine…